Human medicines European public assessment report (EPAR): Ronapreve, casirivimab,imdevimab, Date of authorisation: 12/11/2021, Revision: 9, Status: Authorised
Human medicines European public assessment report (EPAR): Hulio, adalimumab, Date of authorisation: 17/09/2018, Revision: 18, Status: Authorised
Minutes of the PRAC meeting 10-13 February 2025
Human medicines European public assessment report (EPAR): Competact, pioglitazone,metformin, Date of authorisation: 28/07/2006, Revision: 22, Status: Authorised
EU recommendations for 2025/2026 seasonal flu vaccine composition
List of medicines currently in PRIME scheme
Amended Biologics Working Party Vaccines Quality Operational Expert Group (BV-OEG) Influenza Meeting: EU recommendations for the seasonal influenza vaccine composition for the season 2025/2026
Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 24-27 March 2025
Human medicines European public assessment report (EPAR): Besremi, ropeginterferon alfa-2b, Date of authorisation: 15/02/2019, Revision: 7, Status: Authorised
Dear Colleagues,
On behalf of the EFIM Working Group on Diabetes and Obesity, we kindly invite you to help us disseminate a brief survey among your members. The goal is to assess how obesity education is integrated into internal medicine (IM) residency programs across Europe.
The survey is anonymous and takes less than 10 minutes to complete. It is aimed at individuals familiar with IM residency training curricula.
The insights gathered will help us: